Advertisement


Elena Martinez, PhD, MPH, on Diversity in Precision Oncology

2019 Quality Care Symposium

Advertisement

Elena Martinez, PhD, MPH, of Moores Cancer Center at the University of California, San Diego, discusses the challenges of ensuring diversity in precision oncology and potential solutions to address the challenges.



Related Videos

Supportive Care
Cost of Care

Linda D. Bosserman, MD, on Pathways for Personalized Precision Medicine and Value

Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidance for patients with cancer.

Issues in Oncology
Health-Care Policy

Karen M. Winkfield, MD, PhD, on Policy and Business Solutions to Address Disparities in Cancer Care

Karen M. Winkfield, MD, PhD, of the Wake Forest Baptist Medical Center, discusses cultural factors that contribute to cancer care disparities, the role of national policy in addressing inequities in access to care, and what local institutions can do to improve the situation.

Issues in Oncology

Cary P. Gross, MD, on Creating and Implementing Clinical Pathways: Where is the Patient’s Voice?

Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.

Lung Cancer

Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial

Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her institution, enrolling in a therapeutic drug clinical trial was associated with a 47% lower risk of death, compared with not taking part in a trial (Abstract 137).

Cost of Care
Lung Cancer

Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival

Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive non–small cell lung cancer (Abstract 3).

Advertisement

Advertisement




Advertisement